REMER: Medipol Üniversitesi Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi

Tarih: 03.03.2015
Yer: Kandilli Kampüs, AZ-19 13:00- 14:30

Prof. Dr. Gürkan ÖZTÜRK
Medipol Üniversitesi, İstanbul 

Medipol University chose the regenerative medicine as a strategic field for its research. Medipol’s Regenerative and Restorative Medicine Research Center (REMER) is organized to harbor multiple core facilities and labs (received support also from Ministry of Development). It has given priority to four main areas of research within regenerative domain. The first one is repair and regeneration in nervous system disorders that cover a wide range of pathologies from degenerative diseases to stroke and trauma. Though regeneration in the nervous system involves stem cells as in other tissues, re-growth of degenerated neuronal processes and re-establishment of synaptic connections are much more significant for functional recovery. The second main topic is regeneration in the cardiovascular system that entails repair of damaged cardiac tissue and management of vascularization. Studying an extreme animal model of regeneration, the complete re-growth of lost limbs (epimorphic regeneration) and successful repair of damaged organs in a salamander (Ambystoma mexicanum, common name “axolotl”) make our third major research area. Finally the involvement of stem cells in cancer pathogenesis, the dark side of the regenerative biology is among our first four research areas with priority. (brief info modified from REMER’s web site: )

About the Speaker:

Dr Digicaylioglu is a neuroscientist and neurosurgeon with over 20 years of experience. He studies Biology and Medicine in Germany, where he also received his MD. He did his residency in Zurich, Switzerland and also received a PhD in Neuroscience from the University of Zurich. His postodoc experience includes three years at Harvard University and a year at Burnham Institute in California. He was promoted to an assistant professor at UCSD, department of Neurosurgery and to Associate professor at University of Texas Health Science Center in San Antonio, Department of Neurosurgery. Finally he became a full professor in 2014 at the same department. He is currently on sabbatical from that position. Dr. Digicaylioglu's research interest includes investigation of neurodegenerative diseases, brain trauma and brain tumors and related therapies. He has five patents and is the founder of the biotech company Peria. Peria develops nanocarrier based personalized therapies for brain tumors.